Autres langues Mendus AB

Actions

IMMU

SE0022239950

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
7,180 ^SEK	+3,31%		-2,45%	+28,21%

11/09	Mendus publie des résultats positifs pour la première phase de l'essai Vital-CML	CI
11/09	Mendus publie des données de sécurité initiales 'positives' pour le Vididencel dans un essai sur la leucémie myéloïde chronique	MT

Autres langues

11/09	Mendus: Positive safety read-out from VITAL-CML trial
11/09	Mendus Reports Positive Read-Out For First Stage Vital-CML Trial
11/09	Mendus Reports 'Positive' Initial Safety Data for Vididencel in Chronic Myeloid Leukemia Trial
11/09	Mendus reports positive read-out for first stage VITAL-CML trial
24/08	Mendus (Q2 Review): Important CML Readout Near
20/08	Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	MENDUS AB INTERIM REPORT APRIL– JUNE 2026
13/08	Invitation to presentation of Mendus' second quarter 2026 financial report and business update
31/07	Change in number of shares and votes in Mendus AB (publ)
16/07	Mendus announces collaboration with the South Australian Health and Medical Research Institute (SAHMRI) to support preparation of the VITAL-TFR2 trial in chronic myeloid leukemia (CML)
16/07	Mendus AB and South Australian Health and Medical Research Institute Announce Collaboration to Support Preparation of the Vital-TFR2 Trial in Chronic Myeloid Leukemia
08/07	Mendus Completes First Stage Recruitment for Vididencel Trial
08/07	Mendus reports complete enrollment of the first stage of the VITAL-CML trial
08/07	Mendus AB Reports Complete Enrollment of the First Stage of the Vital-Cml Trial
23/06	Mendus AB (publ) has decided on directed issues of Class C shares and transfer of own ordinary shares
10/06	Mendus AB (publ) repurchases outstanding warrants from Fenja
02/06	Mendus reports long-term progression-free survival associated with broad immune activation in high-risk ovarian cancer
02/06	Mendus Reports Additional Positive Results from the Phase 1b Alison Trial in High-Grade Serous Ovarian Cancer
27/05	Mendus AB (publ) has resolved to transfer own shares
13/05	Mendus says vididencel combination potential confirmed
13/05	Preclinical data presented at CIMT confirm combination potential of vididencel with current and upcoming CML treatments
13/05	Mendus AB Presents Preclinical Data Confirming Combination Potential of Vididencel with Current and Upcoming Cml Treatments
11/05	Mendus (Q1 review): CML Phase I Initiated
08/05	Report from the Annual General Meeting of Mendus AB (publ) on 8 May 2026
08/05	Mendus AB Elects Sijmen De Vries as Board Member